BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation® (NYSE: TGX), a medical device company serving the cancer treatment and surgical products markets, today announced consolidated financial results for the third quarter ended October 1, 2006. Consolidated revenue for the quarter was $14.3 million, an increase of $2.3 million, or 19% over the third quarter of 2005. For the nine-month period, consolidated revenue was $39.3 million, an increase of $6.4 million, or 19%, over the same period in 2005. Net income for the quarter was $1.7 million, or $0.05 per share, compared to a net loss of $27.2 million, or $0.85 per share in the third quarter of 2005. For the nine-month period, net income was $2.9 million, or $0.09 per share, compared to a net loss of $28.8 million, or $0.93 per share in the comparable 2005 period. Revenue and net income for the 2006 periods include non-recurring license fee revenue of $400,000 received in connection with the Company’s licensed TheraSphere® technology. The 2005 periods include pre-tax restructuring charges of $32.9 million.
